Cyclin D1

Subscribe to Selected New Research on Cyclin D1

2949 relevant articles (52 outcomes, 437 trials/studies) found for this Bio-Agent

Description: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.

Also Known As:

Proto-Oncogene Products bcl-1; Proto-Oncogene Protein bcl-1; bcl-1 Proto-Oncogene Products; bcl1 Proto-Oncogene Proteins; Proto Oncogene Products bcl 1; Proto Oncogene Protein bcl 1; Proto Oncogene Proteins c bcl 1; Proto-Oncogene Products, bcl-1; Proto-Oncogene Proteins, bcl-1; Proto-Oncogene Proteins, bcl1; bcl 1 Proto Oncogene Products; bcl 1 Proto Oncogene Proteins; bcl-1, Proto-Oncogene Protein; bcl1 Proto Oncogene Proteins; c bcl 1 Proteins; c-bcl-1, Proto-Oncogene Proteins; CCND1 Protein; PRAD1 Protein; Proto-Oncogene Proteins c-bcl-1; bcl-1 Proto-Oncogene Proteins; c-bcl-1 Proteins

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pestell, Richard G: 16 articles (08/2008 - 07/2002)
2.	Weinstein, I Bernard: 7 articles (12/2006 - 06/2002)
3.	Albanese, Chris: 7 articles (09/2005 - 07/2002)
4.	Diehl, J Alan: 6 articles (07/2008 - 05/2002)
5.	Sutherland, Robert L: 6 articles (08/2006 - 01/2002)
6.	Fend, Falko: 4 articles (01/2008 - 04/2003)
7.	Quintanilla-Martinez, Leticia: 4 articles (01/2008 - 04/2003)
8.	Nakashima, Torahiko: 4 articles (06/2007 - 06/2002)
9.	Thakur, Archana: 4 articles (05/2007 - 08/2005)
10.	Biliran, Hector: 4 articles (05/2007 - 08/2005)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2003 - "RESULTS: The overexpression of cyclin D1 was found to be inversely related to disease-free interval (p < 0.001) and to the spindle A/B tumors with good prognosis (p = 0.05). " 08/01/2002 - "Conversely, lack of cyclin D1 expression results in significant reduction in mouse skin and mammary tumor development. " 10/01/1999 - "At univariate analysis, anatomic site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 expression were significantly associated with reduced disease-free and overall survival rates. " 09/01/1998 - "Univariate analysis showed that a shorter disease-free and overall survival were significantly associated with supraglottic site, tumor extension, advanced clinical stage, and cyclin D1 overexpression. " 04/01/1998 - "Therefore, cyclin D1 expression was detected at levels significantly greater than in NBE in the earliest proliferative epithelial lesions of the breast with a further significant increase accompanying the progression to any form of cancer. " Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 08/18/2004 - "We have shown that Pin1 ablation is highly effective in preventing oncogenic Neu or Ras from inducing cyclin D1 and breast cancer in mice, although it neither affects transgene expression nor mammary gland development. " 09/06/2006 - "CONCLUSIONS: Cyclin D1 repression of STAT3 expression may explain the association between cyclin D1 overexpression and improved outcome in breast cancer. " 09/06/2006 - "BACKGROUND: Cyclin D1 is frequently overexpressed in breast cancer, and its overexpression is, surprisingly, associated with improved survival. " 12/01/2008 - "Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study." 01/01/2008 - "Finally, our studies demonstrate that PER 2 expression in MCF-7 breast cancer cells is associated with a significant decrease in the expression of cyclin D1 and an up-regulation of p53 levels." Order ALL the reference details at left...
3.	Retinoblastoma (Glioblastoma, Retinal) 07/01/2004 - "Further immunoprecipitation studies found that, in response to the treatment, the formation of cyclin D1/cdk 4 complex declined, preventing the phosphorylation of retinoblastoma (Rb) and the subsequent dissociation of Rb/E2F complex. " 11/01/2007 - "Restoration of ELF and TBRII in SNU-398 cells markedly decreases cyclin D1 as well as hyperphosphorylated-retinoblastoma (hyperphosphorylated-pRb). " 04/01/2006 - "p16, retinoblastoma (pRb), and cyclin D1 protein expression in human endometriotic and adenomyotic lesions." 02/01/2005 - "Specifically, CWF was shown to downregulate the levels of hyperphosphorylated retinoblastoma tumor-suppressor gene (Rb) and cyclin D1, known to be critical for entering the S phase of the cell cycle. " 01/01/2005 - "ccna2, ccnb1, ccnb2 and ccne) and increased transcript levels of ccnd1, encoding cyclin D1, and orthologs of p21 (p21-like) and retinoblastoma (Rb-like 1). " Order ALL the reference details at left...
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/01/2003 - "CONCLUSIONS: Assessment of p16, cyclin D1, and pRB expression may be helpful for determining postoperative therapeutic strategies in patients with esophageal squamous cell carcinoma." 07/01/2008 - "In this study, we have investigated the role of CCND1 A870G and C1722G polymorphisms on cyclin D1 expression and prognosis in a relatively homogenous population of 178 oral squamous cell carcinoma patients by PCR-SSCP, RFLP, RT-PCR and immunohistochemical methods. " 07/01/2007 - "The aim of the study was to investigate the expression of cyclin D1 and Ki-67 in squamous cell carcinomas (SCC) and in some premalignant lesions of the penis and to correlate it with clinicopathological parameters and patient survival. " 07/01/2007 - "An immunohistochemical study of cyclin D1 protein expression in laryngeal squamous cell carcinoma." 06/01/2007 - "Using immunohistochemical techniques, this study analyzes the prognostic value of three markers (Ki-67, c-erbB2 and Cyclin D1) in cases of low grade squamous intraepithelial neoplasia (CIN-I), high grade squamous intraepithelial neoplasia (CIN-III), and infiltrating squamous cell carcinoma (SCC) taken from a group of cervical samples. " Order ALL the reference details at left...
5.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 09/01/2009 - "Demonstration of cyclin D1 expression by immunohistochemistry in a CD5-positive small B-cell proliferation is extremely helpful in the diagnosis of mantle cell lymphoma in tissue samples, including bone marrow trephine biopsies (BMTB) and in differentiating them from chronic lymphocytic leukaemia (CLL). " 06/01/2004 - "Since immunohistochemical demonstration of cyclin D1 is notoriously difficult, this study aims to assess whether a newly available rabbit MAb against cyclin D1 (SP4) can improve the consistency of immunostaining, especially for the diagnosis of mantle cell lymphoma (MCL). " 05/01/2004 - "Our study indicates that cyclin D1/IgH-fusion fluorescence in situ hybridization analysis could be used to determine the presence and character of circulating mantle cell lymphoma cells in peripheral blood, thus enhancing our ability to evaluate leukemic mantle cell lymphoma and minimum residual disease." 05/01/2004 - "In this study, we performed cyclin D1/IgH-probe fusion fluorescence in situ hybridization analysis on 223 peripheral blood samples: 185 from 125 mantle cell lymphoma patients, and 38 normal controls. " 08/01/1998 - "Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Cyclins
3.	cyclin D3
4.	Retinoblastoma Protein
5.	Proteins (Proteins, Gene)
6.	Messenger RNA (mRNA)
7.	Fenretinide
8.	4-(1H-imidazol-1-yl)retinoic acid
9.	beta Catenin
10.	Proliferating Cell Nuclear Antigen (PCNA)

Related Therapies and Procedures

1.	Chemoprevention
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Oral Administration
5.	Prostatectomy (Retropubic Prostatectomy)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>